Component

Albumin-bound paclitaxel formulation

Drug formulation used as a cointervention; not identical to free paclitaxel or albumin alone.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. Median progression-free survival was 6.2 versus 3.9 months (HR 0.43; 90% CI 0.20–0.92; P=0.029).

    L-Ascorbate → Progression-free survival in pancreatic cancer source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    Unblinded randomized phase II metastatic pancreatic cancer trial at two academic sites: 36 randomized, 34 received assigned therapy and entered analysis.
    exposure
    Gemcitabine and nab-paclitaxel with or without IV pharmacologic ascorbate 75 g three times weekly.
    limitations
    Small unblinded trial; a planned futility interim analysis was followed by efficacy-based closure supported by the monitoring committee, without a stated prespecified efficacy boundary. 34 treated/evaluable of 36 randomized, 90% rather than 95% intervals, one-sided design. Tumor redox mediators were not measured; requires confirmation and does not support replacing chemotherapy.
    nutrient_topic
    Vitamin C research collection; topical membership is not evidence of a direct dietary effect. · Vitamin C
    organism
    Homo sapiens
    plain_language
    The treated group also had a longer measured interval before progression or death.
    primary_references
    [c-bodeker2024] A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer (2024). https://pubmed.ncbi.nlm.nih.gov/39369582/ DOI: 10.1016/j.redox.2024.103375
    tissue_or_cell_type
    Human blood or whole-person endpoints

    Vitamin C: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1818–1828

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Unblinded randomized phase II metastatic pancreatic cancer trial at two academic sites: 36 randomized, 34 received assigned therapy and entered analysis. · source_derived_draft · unverified_draft

    ### c-iv-pancreas-progression-signal Median progression-free survival was 6.2 versus 3.9 months (HR 0.43; 90% CI 0.20–0.92; P=0.029). Condition category: normal nutrient_topic: Vitamin C research collection; topical membership is not evidence of a direct dietary effect. plain_language: The treated group also had a longer measured interval before progression or death. organism: Homo sapiens tissue_or_cell_type: Human blood or whole-person endpoints experimental_model: Unblinded randomized phase II metastatic pancreatic cancer trial at two academic sites: 36 randomized, 34 received assigned therapy and entered analysis. limitations: Small unblinded trial; a planned futility interim analysis was followed by efficacy-based closure supported by the monitoring committee, without a stated prespecified efficacy boundary. 34 treated/evaluable of 36 randomized, 90% rather than 95% intervals, one-sided design. Tumor redox mediators were not measured; requires confirmation and does not support replacing chemotherapy. exposure: Gemcitabine and nab-paclitaxel with or without IV pharmacologic ascorbate 75 g three times weekly. [c-bodeker2024] A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer (2024). https://pubmed.ncbi.nlm.nih.gov/39369582/ DOI: 10.1016/j.redox.2024.103375
    Complete structured claim and evidence

  2. Median overall survival was 16 versus 8.3 months with versus without added IV ascorbate (HR 0.46; 90% CI 0.23–0.92; P=0.030).

    L-Ascorbate → Overall survival in pancreatic cancer source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    Unblinded randomized phase II metastatic pancreatic cancer trial at two academic sites: 36 randomized, 34 received assigned therapy and entered analysis.
    exposure
    Gemcitabine and nab-paclitaxel with or without IV pharmacologic ascorbate 75 g three times weekly.
    limitations
    Small unblinded trial; a planned futility interim analysis was followed by efficacy-based closure supported by the monitoring committee, without a stated prespecified efficacy boundary. 34 treated/evaluable of 36 randomized, 90% rather than 95% intervals, one-sided design. Tumor redox mediators were not measured; requires confirmation and does not support replacing chemotherapy.
    nutrient_topic
    Vitamin C research collection; topical membership is not evidence of a direct dietary effect. · Vitamin C
    organism
    Homo sapiens
    plain_language
    Adding the infusions to the two-drug regimen produced a promising survival signal in this small study.
    primary_references
    [c-bodeker2024] A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer (2024). https://pubmed.ncbi.nlm.nih.gov/39369582/ DOI: 10.1016/j.redox.2024.103375
    tissue_or_cell_type
    Human blood or whole-person endpoints

    Vitamin C: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1806–1816

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Unblinded randomized phase II metastatic pancreatic cancer trial at two academic sites: 36 randomized, 34 received assigned therapy and entered analysis. · source_derived_draft · unverified_draft

    ### c-iv-pancreas-survival-signal Median overall survival was 16 versus 8.3 months with versus without added IV ascorbate (HR 0.46; 90% CI 0.23–0.92; P=0.030). Condition category: normal nutrient_topic: Vitamin C research collection; topical membership is not evidence of a direct dietary effect. plain_language: Adding the infusions to the two-drug regimen produced a promising survival signal in this small study. organism: Homo sapiens tissue_or_cell_type: Human blood or whole-person endpoints experimental_model: Unblinded randomized phase II metastatic pancreatic cancer trial at two academic sites: 36 randomized, 34 received assigned therapy and entered analysis. limitations: Small unblinded trial; a planned futility interim analysis was followed by efficacy-based closure supported by the monitoring committee, without a stated prespecified efficacy boundary. 34 treated/evaluable of 36 randomized, 90% rather than 95% intervals, one-sided design. Tumor redox mediators were not measured; requires confirmation and does not support replacing chemotherapy. exposure: Gemcitabine and nab-paclitaxel with or without IV pharmacologic ascorbate 75 g three times weekly. [c-bodeker2024] A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer (2024). https://pubmed.ncbi.nlm.nih.gov/39369582/ DOI: 10.1016/j.redox.2024.103375
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards